bezafibrate has been researched along with Disease Models, Animal in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.70) | 18.7374 |
| 1990's | 1 (2.70) | 18.2507 |
| 2000's | 9 (24.32) | 29.6817 |
| 2010's | 24 (64.86) | 24.3611 |
| 2020's | 2 (5.41) | 2.80 |
| Authors | Studies |
|---|---|
| Aoki, T; Asaki, T; Hamamoto, T; Kuwabara, K; Murakami, K; Ohmachi, S; Sugiyama, Y; Todo, M | 1 |
| Abuo-Rahma, Gel-D; Aly, OM; Idrees, GA; Radwan, MF | 1 |
| Bahekar, R; Giri, S; Jain, M; Makadia, P; Patel, D; Patel, P; Pingali, H; Pola, S; Priyadarshini, P; Shah, M; Shah, SR; Suthar, D; Thube, B; Trivedi, C; Zaware, P | 1 |
| Braisted, J; Dranchak, P; Earnest, TW; Gu, X; Hoon, MA; Inglese, J; Oliphant, E; Solinski, HJ | 1 |
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Ji, K; Lyu, J; Xin, W; Xu, X; Yan, C; Yu, W; Zhang, N; Zhao, Y; Zheng, R | 1 |
| Haußmann-Vopel, S; Lehmann, C; Pavlovic, D; Wegner, A | 1 |
| Brooks, ED; Grant, S; Huat, BB; Koeberl, DD; Kudo, T; Landau, DJ; Lim, A; Waskowicz, LR; Wu, Y; Yavarow, ZA; Yen, PM; Young, SP; Zhang, H; Zhou, J | 1 |
| Jiao, S; Li, Q; Pan, M; Qu, J; Reinach, PS; Srinivasalu, N; Yan, J; Yang, Y; Zhou, X | 1 |
| Bandyopadhyay, A; Chander, V; De, K; Kar, D; Maity, S | 1 |
| Ackerman, Z; Ben-Ari, Z; Chepurko, Y; Cohen, M; Grossman, E; Hochhauser, E; Leibowitz, A; Schmilovitz-Weiss, H; Yitzhaki, S | 1 |
| Komen, JC; Thorburn, DR | 1 |
| Capdevila, JH; Chen, X; Falck, JR; Gangadhariah, M; Hu, W; Jat, JL; Mont, S; Pozzi, A; Skrypnyk, N; Su, Y; Wei, S; Yang, S; Zent, R | 1 |
| Ackerman, Z; Grozovski, M; Oron-Herman, M; Sela, BA; Skarzinski, G | 1 |
| Cao, B; Lin, B; Lin, D; Lin, Y | 1 |
| Beal, MF; Calingasan, NY; Chandra, A; Johri, A; Sharma, A; Shurubor, Y; White, JM; Yang, XW | 1 |
| Aichler, M; Brachthäuser, L; Feuchtinger, A; Franko, A; Fuchs, H; Häring, HU; Hrabě de Angelis, M; Kovarova, M; Neff, F; Neschen, S; Peter, A; Rathkolb, B; Rozman, J; Wolf, E | 1 |
| Glukhov, AV; Huang, Y; James, JF; Javadov, S; Jefferies, JL; Khuchua, Z; Moore, V; Phoon, CK; Powers, C; Ren, M; Schafer, C; Strauss, AW; Vaz, FM | 1 |
| Banerjee, A; Lee, JH; Ramaiah, SK; Ueno, Y | 1 |
| Fujita, N; Furukawa, Y; Inaba, T; Ishibashi, S; Itabashi, N; Nagashima, S; Okada, K; Okazaki, M; Tazoe, F; Yagyu, H | 1 |
| Diaz, F; Moraes, CT; Spiegelman, BM; Wenz, T | 1 |
| Bordet, R; Destée, A; Duhamel, A; Kreisler, A; Vanbesien-Mailliot, C | 1 |
| DiMauro, S | 1 |
| Aburada, M; Hokao, R; Iizuka, S; Makihara, H; Sasaki, Y; Shimada, T; Suzuki, W; Teraoka, R; Tsuneyama, K | 1 |
| Bottani, E; Cerutti, R; Civiletto, G; Fagiolari, G; Lamperti, C; Moggio, M; Schon, EA; Viscomi, C; Zeviani, M | 1 |
| Katsuya, T; Kiomy Osako, M; Koriyama, H; Kyutoku, M; Minobe, N; Miyake, T; Morishita, R; Moritani, T; Nakagami, F; Nakagami, H; Shimamura, M; Shimizu, H; Shimosato, T | 1 |
| Beal, MF; Calingasan, NY; Chandra, A; Hennessey, TM; Johri, A; Sharma, A; Wille, E; Yang, L | 1 |
| Beal, MF; Calingasan, NY; Chan, RB; Di Paolo, G; Dumont, M; Elipenahli, C; Gerges, M; Jainuddin, S; Pujol, A; Stack, C; Starkov, AA; Starkova, N; Tampellini, D; Yang, L | 1 |
| Dou, X; Gu, D; Li, S; Shen, C; Song, Z; Wang, Z; Yao, T | 1 |
| Diaz, F; Dillon, L; Hida, A; Lellek, V; Moraes, CT; Noe, N; Wenz, T | 1 |
| Fujisaki, K; Itoh, Y; Maiguma, T; Makino, K; Oishi, R; Sasaguri, T; Takahashi-Yanaga, F; Teshima, D | 1 |
| Burns, AM; Gonzalez, FJ; Hays, T; Kennett, MJ; Peters, JM; Rusyn, I; Ward, JM | 1 |
| Adler, Y; Behar, S; Benderly, M; Fisman, EZ; Fujita, K; Funahashi, T; Hibuse, T; Hiuge, A; Kihara, S; Kumada, M; Maeda, N; Matas, Z; Motro, M; Nishizawa, H; Shimomura, I; Tanne, D; Tenenbaum, A | 1 |
| Bordet, R; Destée, A; Gelé, P; Kreisler, A; Lhermitte, M; Wiart, JF | 1 |
| Friedman, M; Gilhar, D; Hoffman, A; Lomnicky, Y; Luria, MH | 1 |
| Aspey, BS; Ehteshami, S; Harrison, MJ; Hurst, CM; Pereira, S | 1 |
2 review(s) available for bezafibrate and Disease Models, Animal
| Article | Year |
|---|---|
Turn up the power - pharmacological activation of mitochondrial biogenesis in mouse models.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Bezafibrate; Disease Models, Animal; Energy Metabolism; Mitochondria; Mitochondrial Diseases; Mitochondrial Turnover; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Resveratrol; Ribonucleotides; Sirtuin 1; Stilbenes; Transcription Factors; Up-Regulation | 2014 |
Pathogenesis and treatment of mitochondrial myopathies: recent advances.
Topics: Animals; Bezafibrate; Disease Models, Animal; DNA, Mitochondrial; Hematopoietic Stem Cell Transplantation; Humans; Mitochondrial Myopathies; Mutation; Nuclear Transfer Techniques | 2010 |
1 trial(s) available for bezafibrate and Disease Models, Animal
| Article | Year |
|---|---|
Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level.
Topics: Adipocytes; Adiponectin; Adult; Analysis of Variance; Animals; Bezafibrate; Cells, Cultured; Disease Models, Animal; Double-Blind Method; Female; Fenofibrate; Gene Expression Regulation; Humans; Hypolipidemic Agents; Ligands; Male; Metabolic Syndrome; Mice; Mice, Knockout; Middle Aged; Peroxisome Proliferator-Activated Receptors; Probability; Prospective Studies; RNA, Messenger; Statistics, Nonparametric; Stromal Cells | 2007 |
34 other study(ies) available for bezafibrate and Disease Models, Animal
| Article | Year |
|---|---|
Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dioxanes; Disease Models, Animal; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred Strains; Molecular Structure; Oxazoles; PPAR alpha; Structure-Activity Relationship; Triglycerides | 2008 |
Design, synthesis and hypolipidemic activity of novel 2-(m-tolyloxy) isobutyric acid derivatives.
Topics: Animals; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; Drug Design; Gemfibrozil; Hypolipidemic Agents; Male; Molecular Structure; Propionates; Rats; Rats, Wistar; Stereoisomerism; Triglycerides | 2009 |
Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.
Topics: Animals; Cricetinae; Disease Models, Animal; Ether; Hep G2 Cells; Humans; Hypoglycemic Agents; Male; Mice; Mice, Obese; Oximes; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR delta; PPAR gamma; Structure-Activity Relationship; Thiazoles | 2011 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, Spinal; Humans; Mice, Inbred C57BL; Mice, Knockout; Neurons; Pruritus; Receptors, Atrial Natriuretic Factor; Reproducibility of Results; Signal Transduction; Small Molecule Libraries | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Bezafibrate Rescues Mitochondrial Encephalopathy in Mice via Induction of Daily Torpor and Hypometabolic State.
Topics: Animals; Bezafibrate; Disease Models, Animal; Electron Transport Complex I; Hypoglycemic Agents; Mice; Mice, Knockout; Mitochondrial Encephalomyopathies; Peroxisome Proliferator-Activated Receptors; Torpor | 2022 |
Topics: Animals; Bezafibrate; Disease Models, Animal; Energy Metabolism; Humans; Immunotherapy; Lymph Nodes; Mice; Mitochondria; Neoplasms; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Programmed Cell Death 1 Receptor; Reactive Oxygen Species; T-Lymphocytes; T-Lymphocytes, Cytotoxic | 2017 |
Impact of lipid modulation on the intestinal microcirculation in experimental sepsis.
Topics: Animals; Anti-Inflammatory Agents; Bezafibrate; Blood Flow Velocity; Capillaries; Cytokines; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Intestines; Intravital Microscopy; Leukocyte Rolling; Lipid Metabolism; Lipopolysaccharides; Lipoproteins, HDL; Male; Microcirculation; Microscopy, Fluorescence; Microscopy, Video; Rats, Inbred Lew; Regional Blood Flow; Sepsis; Simvastatin | 2018 |
Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia.
Topics: Animals; Autophagy; Bezafibrate; Disease Models, Animal; Dogs; Glucose; Glucose-6-Phosphatase; Glucose-6-Phosphate; Glycogen; Glycogen Storage Disease Type I; Lipid Metabolism; Liver; Mice; Mice, Knockout; Triglycerides | 2019 |
Opposing Effects of PPARα Agonism and Antagonism on Refractive Development and Form Deprivation Myopia in Guinea Pigs.
Topics: Animals; Apolipoprotein A-II; Bezafibrate; Biometry; Blotting, Western; Butyrates; Clofibrate; Collagen Type I; Disease Models, Animal; Electroretinography; Fluorescent Antibody Technique, Indirect; Guinea Pigs; Intraocular Pressure; Malate Dehydrogenase; Myopia; Oxazoles; Phenylurea Compounds; PPAR alpha; Refraction, Ocular; Sensory Deprivation; Tyrosine | 2018 |
Hyperthyroidism causes cardiac dysfunction by mitochondrial impairment and energy depletion.
Topics: Adenosine Triphosphate; Animals; Bezafibrate; Cardiomegaly; Disease Models, Animal; Down-Regulation; Electron Transport Complex IV; Energy Metabolism; Fatty Acids; Female; Hyperthyroidism; Mitochondria, Heart; Oxidative Stress; PPAR alpha; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Triiodothyronine | 2013 |
Rosiglitazone and bezafibrate modulate gene expression in a rat model of non-alcoholic fatty liver disease--a historical prospective.
Topics: Animals; Bezafibrate; Disease Models, Animal; Fatty Liver; Fructose; Gene Expression; Hypoglycemic Agents; Hypolipidemic Agents; Liver; Male; Non-alcoholic Fatty Liver Disease; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Superoxide Dismutase; Thiazolidinediones | 2013 |
PPARα activation can help prevent and treat non-small cell lung cancer.
Topics: Animals; Arachidonic Acids; Bezafibrate; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 2; Disease Models, Animal; Endothelial Cells; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; PPAR alpha; Pyrimidines | 2014 |
Effects of antihypertensive and triglyceride-lowering agents on hepatic copper concentrations in rats with fatty liver disease.
Topics: Animals; Antihypertensive Agents; Bezafibrate; Captopril; Copper; Disease Models, Animal; Fatty Liver; Hypolipidemic Agents; Liver; Male; Metallothionein; Rats, Sprague-Dawley; Superoxide Dismutase | 2014 |
Effects of Bezafibrate on the Survival of Random Skin Flaps in Rats.
Topics: Animals; Bezafibrate; Disease Models, Animal; Dose-Response Relationship, Drug; Graft Survival; Hypolipidemic Agents; Injections, Intraperitoneal; Male; Peroxisome Proliferator-Activated Receptors; Rats; Rats, Sprague-Dawley; Skin Transplantation; Superoxide Dismutase; Surgical Flaps; Vascular Endothelial Growth Factor A | 2016 |
Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease.
Topics: Animals; Bezafibrate; Corpus Striatum; Disease Models, Animal; Humans; Huntingtin Protein; Huntington Disease; Mice; Mice, Transgenic; Mitochondria; Organelle Biogenesis; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; PPAR delta; PPAR gamma; Signal Transduction | 2016 |
Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice.
Topics: Animals; Bezafibrate; Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Experimental; Disease Models, Animal; Fatty Liver; Glucose; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Obesity; Peroxisome Proliferator-Activated Receptors | 2017 |
The PPAR pan-agonist bezafibrate ameliorates cardiomyopathy in a mouse model of Barth syndrome.
Topics: Animals; Barth Syndrome; Bezafibrate; Blotting, Western; Cardiolipins; Cardiomyopathies; Disease Models, Animal; Echocardiography; Female; Male; Mice; Peroxisome Proliferator-Activated Receptors; Polymerase Chain Reaction | 2017 |
Potential relationship between hepatobiliary osteopontin and peroxisome proliferator-activated receptor alpha expression following ethanol-associated hepatic injury in vivo and in vitro.
Topics: Acetaldehyde; Animals; Bezafibrate; Bile Ducts; Cell Line, Tumor; Disease Models, Animal; Epithelial Cells; Ethanol; Hepatocytes; Humans; Lipopolysaccharides; Liver; Liver Diseases, Alcoholic; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Osteopontin; PPAR alpha; Rats; Rats, Sprague-Dawley; RNA, Messenger; Transcription, Genetic; Transfection | 2008 |
Cholesterol reduction and atherosclerosis inhibition by bezafibrate in low-density lipoprotein receptor knockout mice.
Topics: Animals; Aorta; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Bezafibrate; Blood Glucose; Chemokine CCL2; Cholesterol, HDL; Disease Models, Animal; Hypolipidemic Agents; Lipids; Lipoprotein Lipase; Lipoproteins; Liver; Mice; Mice, Inbred C57BL; Mice, Knockout; Receptors, LDL; RNA, Messenger; Triglycerides | 2008 |
Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype.
Topics: Adenosine Triphosphate; Animals; Bezafibrate; Cytochrome-c Oxidase Deficiency; Disease Models, Animal; Energy Metabolism; Female; Mice; Mice, Inbred Strains; Mice, Transgenic; Mitochondria, Muscle; Mitochondrial Myopathies; Muscle, Skeletal; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Phenotype; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Survival Rate; Trans-Activators; Transcription Factors; Transgenes | 2008 |
Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Bezafibrate; Cell Count; Disease Models, Animal; Drug Interactions; Exploratory Behavior; Fenofibrate; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Statistics, Nonparametric; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase; Ventral Tegmental Area | 2010 |
Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome.
Topics: Adipose Tissue; Animals; Bezafibrate; Diabetes Mellitus; Disease Models, Animal; Eating; Fatty Liver; Gene Expression Regulation; Glucose Tolerance Test; Glycosuria; Hypolipidemic Agents; Lipid Metabolism; Liver; Male; Metabolic Syndrome; Mice; Non-alcoholic Fatty Liver Disease; Obesity; Organ Size; RNA, Messenger; Sodium Glutamate | 2011 |
In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Bezafibrate; Cytochrome-c Oxidase Deficiency; Disease Models, Animal; Electron Transport Complex IV; Gene Knock-In Techniques; Hypoglycemic Agents; Hypolipidemic Agents; Membrane Proteins; Mice; Mice, Knockout; Mice, Transgenic; Mitochondrial Proteins; Molecular Chaperones; Muscle, Skeletal; Oxidative Phosphorylation; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Ribonucleotides; Signal Transduction; Trans-Activators; Transcription Factors | 2011 |
Nifedipine prevents hepatic fibrosis in a non-alcoholic steatohepatitis model induced by an L-methionine-and choline-deficient diet.
Topics: Alanine Transaminase; Animals; Bezafibrate; Calcium Channel Blockers; Choline Deficiency; Diet; Disease Models, Animal; Fatty Liver; Hypolipidemic Agents; Liver; Liver Cirrhosis, Experimental; Male; Methionine; Nifedipine; Non-alcoholic Fatty Liver Disease; PPAR gamma; Rats; Rats, Wistar | 2012 |
Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease.
Topics: Adipose Tissue, Brown; Animals; Bezafibrate; Corpus Striatum; Diet; Disease Models, Animal; Gliosis; Huntington Disease; Mice; Mice, Transgenic; Mitochondria; Mitochondria, Muscle; Muscle Fibers, Skeletal; Neurons; Neuroprotective Agents; Oxidative Stress; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Phenotype; PPAR gamma; Signal Transduction; Survival Rate; Trans-Activators; Transcription Factors; Transcriptional Activation; Vacuoles | 2012 |
Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice.
Topics: Adipose Tissue, Brown; Animals; Behavior, Animal; Bezafibrate; Disease Models, Animal; Energy Metabolism; Fatty Acids; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Inflammation; Mice; Mice, Transgenic; Oxidation-Reduction; Oxidative Stress; Phosphorylation; tau Proteins; Tauopathies | 2012 |
Inhibition of NF-κB activation by 4-hydroxynonenal contributes to liver injury in a mouse model of alcoholic liver disease.
Topics: Acetylcysteine; Aldehydes; Animals; Bezafibrate; Caspases; Cell Death; Cytoprotection; Disease Models, Animal; Enzyme Activation; Ethanol; Hep G2 Cells; Hepatocytes; Humans; I-kappa B Proteins; JNK Mitogen-Activated Protein Kinases; Liver; Liver Diseases, Alcoholic; Male; Mice; Mice, Inbred C57BL; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Time Factors; Transcriptional Activation; Tumor Necrosis Factor-alpha | 2012 |
RETRACTED: Bezafibrate improves mitochondrial function in the CNS of a mouse model of mitochondrial encephalopathy.
Topics: Adenosine Triphosphate; Alkyl and Aryl Transferases; Animals; Astrocytes; Bezafibrate; Cell Proliferation; Disease Models, Animal; Hypolipidemic Agents; Membrane Proteins; Mice; Mitochondria; Mitochondrial Encephalomyopathies; Mitochondrial Proteins; Neuroprotective Agents; Treatment Outcome | 2013 |
Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells.
Topics: Bezafibrate; Clofibrate; Clofibric Acid; Disease Models, Animal; Drug Synergism; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Rhabdomyosarcoma, Embryonal; RNA, Messenger; Simvastatin; Time Factors; Transcription Factors; Tumor Cells, Cultured | 2003 |
Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis.
Topics: Acyl-CoA Oxidase; Animals; Bezafibrate; Bile Acids and Salts; Blotting, Northern; Cell Cycle Proteins; Cholestasis; Cytochrome P-450 CYP4A; Disease Models, Animal; DNA Repair Enzymes; DNA-Binding Proteins; Liver Neoplasms; Male; Mice; Peroxisome Proliferators; PPAR alpha; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Transcription Factors | 2005 |
Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acyl Coenzyme A; Analysis of Variance; Animals; Bezafibrate; Cell Death; Disease Models, Animal; Drug Interactions; Fenofibrate; Hypolipidemic Agents; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase; MPTP Poisoning; PPAR alpha; Substantia Nigra | 2007 |
Improved lipid lowering activity of bezafibrate following continuous gastrointestinal administration: pharmacodynamic rationale for sustained release preparation of the drug.
Topics: Animals; Bezafibrate; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Delayed-Action Preparations; Disease Models, Animal; Drug Administration Routes; Duodenum; Enzyme Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipase; Lipids; Lipoproteins, HDL; Male; Polyethylene Glycols; Rats; Rats, Inbred Lew; Surface-Active Agents | 1999 |
Effect of bezafibrate on the sequelae of acute experimental focal cerebral ischaemia.
Topics: Acute Disease; Animals; Bezafibrate; Brain Ischemia; Disease Models, Animal; Gerbillinae; Hemoglobins; Lactates; Male; Oxygen; Rats; Rats, Inbred Strains | 1989 |